Huarong Holdings: terminate the purchase of 100% equity of Xinchao biology and resume trading tomorrow

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Unpacking China | Key Chinese Firms to Watch This Week （26/07/2026-01/08/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar

Mabwell (Shanghai) Bioscience Co., Ltd.（迈威（上海）生物科技股份有限公司）has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.

Zhongji InnoLight Prices Hong Kong Listing at HK$980, Raising HK$53.41 Billion

Zhongji InnoLight Co., Ltd.（中际旭创股份有限公司）, a leading Chinese supplier of optical transceivers used in cloud and artificial-intelligence infrastructure, has priced its Hong Kong H-share offering at HK$980 per share, giving the base deal gross proceeds of HK$53.41 billion (US$6.81 billion).

Unpacking China | Key Chinese Firms to Watch This Week （19/07/2026-25/07/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.